Listed

Innate Pharma SA: Form 20-F for the period ended Dec 31, 2025

Filed with the SEC on Apr 1, 2026 and accepted by EDGAR at Apr 1, 2026, 06:08 ET.

Share

Share this page

Story card, 1080 × 1920

Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2025-12-31. Comparative periods it repeats are left out.

Line itemPeriodValueXBRL concept
Revenue12 months2025-01-01 to 2025-12-31EUR 9.0mifrs-full:Revenue
Operating income12 months2025-01-01 to 2025-12-31−EUR 54.0mifrs-full:ProfitLossFromOperatingActivities
Income tax12 months2025-01-01 to 2025-12-31EUR 0ifrs-full:IncomeTaxExpenseContinuingOperations
Net income12 months2025-01-01 to 2025-12-31−EUR 49.2mifrs-full:ProfitLoss
Diluted EPS12 months2025-01-01 to 2025-12-31−EUR 0.55ifrs-full:DilutedEarningsLossPerShare
Basic EPS12 months2025-01-01 to 2025-12-31−EUR 0.55ifrs-full:BasicEarningsLossPerShare
Operating cash flow12 months2025-01-01 to 2025-12-31−EUR 52.8mifrs-full:CashFlowsFromUsedInOperatingActivities
Capital expenditure12 months2025-01-01 to 2025-12-31EUR 140.0kifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
Cash and equivalentsAt period end2025-12-31EUR 28.1mifrs-full:CashAndCashEquivalents
Current assetsAt period end2025-12-31EUR 46.7mifrs-full:CurrentAssets
Total assetsAt period end2025-12-31EUR 62.7mifrs-full:Assets
Current liabilitiesAt period end2025-12-31EUR 36.6mifrs-full:CurrentLiabilities
Shareholders' equityAt period end2025-12-31−EUR 21.7mifrs-full:Equity
Shares outstandingAt period end2025-12-3193,719,323 sharesdei:EntityCommonStockSharesOutstanding

Source: SEC EDGAR, the filing index for accession 0001598599-26-000005. Last ingested by Listed: Nov 5, 2026, 11:30 ET. Listed shows no prices and gives no investment advice.